Evolus Q2 revenue rises 21%, lifts 2026 outlook

Evolus

05/08/2026 21:48

Overview
US injectable aesthetics firm's Q2 revenue grew 21% yr/yr, driven by market share gains
Company delivered third consecutive quarter of positive adjusted EBITDA, reflecting improved operating leverage
Full-year 2026 revenue and margin guidance raised, citing healthy demand and portfolio expansion

Outlook
Evolus raises 2026 net revenue guidance to $330 mln-$337 mln, up from $327 mln-$337 mln
Company lifts 2026 adjusted gross profit margin outlook to 67.0%-67.5%, from 65.5%-67.0%
Evolus reaffirms 2026 low- to mid-single digit adjusted EBITDA margin outlook

Result Drivers
PRODUCT GROWTH - Double-digit growth for Jeuveau and increased adoption of Evolysse drove revenue gains, per CEO David Moatazedi
CONSUMER DEMAND - Healthy consumer demand, increased customer penetration, and strong reorder behavior supported commercial execution
PORTFOLIO EXPANSION - Launch of Estyme collection in Europe and expansion into Canada, Australia, and New Zealand broadened international growth opportunity

Company press release: ID:nBw2CRTn8a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
 
$83.35 mln
 
Q2 Net Loss
 
$8.05 mln
 
Q2 Gross Profit
 
$57.18 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Evolus Inc is $14.00, about 128.8% above its August 4 closing price of $6.12

Reuters Recommended Reads
Aug 5 - InMode Q2 revenue beats estimates on steady U.S. demand
Aug 4 - Sofwave Medical's Q2 revenue rises on usage fee growth
Aug 5 - Elf Beauty raises annual forecasts as value bet pays off

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)